{"doc_id": "32977137", "type of study": "Therapy", "title": "", "abstract": "Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).\nCoronavirus disease 2019 (COVID-19) causes a hypercoagulable state.\nSeveral autopsy studies have found microthrombi in pulmonary circulation.\nIn this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard anticoagulant thromboprophylaxis.\nWe evaluated the gas exchange over time through the ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at baseline, 7, and 14\u00a0days after randomization, the time until successful liberation from mechanical ventilation, and the ventilator-free days.\nTen patients were assigned to the therapeutic enoxaparin and ten patients to prophylactic anticoagulation.\nThere was a statistically significant increase in the PaO2/FiO2 ratio over time in the therapeutic group (163 [95% confidence interval - CI 133-193] at baseline, 209 [95% CI 171-247] after 7\u00a0days, and 261 [95% CI 230-293] after 14\u00a0days), p\u00a0=\u00a00.0004.\nIn contrast, we did not observe this improvement over time in the prophylactic group (184 [95% CI 146-222] at baseline, 168 [95% CI 142-195] after 7\u00a0days, and 195 [95% CI 128-262] after 14\u00a0days), p\u00a0=\u00a00.487.\nPatients of the therapeutic group had a higher ratio of successful liberation from mechanical ventilation (hazard ratio: 4.0 [95% CI 1.035-15.053]), p\u00a0=\u00a00.031 and more ventilator-free days (15\u00a0days [interquartile range IQR 6-16] versus 0\u00a0days [IQR 0-11]), p\u00a0=\u00a00.028 when compared to the prophylactic group.\nTherapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID-19.\nTRIAL REGISTRATION : REBEC RBR-949z6v.\nCopyright \u00a9 2020.\nPublished by Elsevier Ltd.\n", "Evidence Map": {"Enrollment": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 67}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 73}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 115}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 113}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Therapeutic versus prophylactic anticoagulation for severe COVID-19 : A randomized phase II clinical trial ( HESACOVID ) .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 67}], "Intervention": [{"term": "Therapeutic", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11}, {"term": "prophylactic anticoagulation", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 47}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Coronavirus disease 2019 ( COVID-19 ) causes a hypercoagulable state .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Several autopsy studies have found microthrombi in pulmonary circulation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this randomized , open-label , phase II study , we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard anticoagulant thromboprophylaxis .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 73}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 115}], "Intervention": [{"term": "therapeutic enoxaparin", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 156}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We evaluated the gas exchange over time through the ratio of partial pressure of arterial oxygen ( PaO2 ) to the fraction of inspired oxygen ( FiO2 ) at baseline , 7 , and 14 days after randomization , the time until successful liberation from mechanical ventilation , and the ventilator-free days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "gas exchange", "negation": "negated", "UMLS": {}, "start": 17, "end": 29}, {"term": "ratio of partial pressure of arterial oxygen ( PaO2 ) to the fraction of inspired oxygen ( FiO2 )", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 149}, {"term": "time until successful liberation", "negation": "negated", "UMLS": {}, "start": 206, "end": 238}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Ten patients were assigned to the therapeutic enoxaparin and ten patients to prophylactic anticoagulation .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "enoxaparin", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 56}], "Outcome": [{"term": "prophylactic anticoagulation", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 105}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There was a statistically significant increase in the PaO2 / FiO2 ratio over time in the therapeutic group ( 163 [ 95 % confidence interval -CI 133-193 ] at baseline , 209 [ 95 % CI 171-247 ] after 7 days , and 261 [ 95 % CI 230-293 ] after 14 days ) , p=0.0004 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "therapeutic", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 100}], "Outcome": [{"term": "FiO2 ratio", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 71}], "Observation": [{"term": "statistically significant increase", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 46}, {"term": "163", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 112}, {"term": "261", "negation": "affirmed", "UMLS": {}, "start": 211, "end": 214}], "Count": []}, "Evidence Propositions": [{"Intervention": "therapeutic", "Observation": "statistically significant increase", "Outcome": "FiO2 ratio", "Count": ""}, {"Intervention": "therapeutic", "Observation": "261", "Outcome": "FiO2 ratio", "Count": ""}]}, {"Section": "RESULTS", "Text": "In contrast , we did not observe this improvement over time in the prophylactic group ( 184 [ 95 % CI 146-222 ] at baseline , 168 [ 95 % CI 142-195 ] after 7 days , and 195 [ 95 % CI 128-262 ] after 14 days ) , p=0.487 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "prophylactic", "negation": "negated", "UMLS": {}, "start": 67, "end": 79}], "Outcome": [], "Observation": [{"term": "improvement", "negation": "negated", "UMLS": {}, "start": 38, "end": 49}, {"term": "184", "negation": "negated", "UMLS": {}, "start": 88, "end": 91}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Patients of the therapeutic group had a higher ratio of successful liberation from mechanical ventilation ( hazard ratio : 4.0 [ 95 % CI 1.035-15.053 ] ) , p=0.031 and more ventilator-free days (15 days [ interquartile range IQR 6-16 ] versus 0 days [ IQR 0-11 ] ) , p=0.028 when compared to the prophylactic group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "therapeutic", "negation": "negated", "UMLS": {}, "start": 16, "end": 27}], "Outcome": [{"term": "ratio of successful liberation from mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 47, "end": 105}, {"term": "ventilator-free days", "negation": "affirmed", "UMLS": {}, "start": 173, "end": 193}], "Observation": [{"term": "higher", "negation": "negated", "UMLS": {}, "start": 40, "end": 46}, {"term": "more", "negation": "negated", "UMLS": {}, "start": 168, "end": 172}, {"term": "days", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 193}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "higher", "Outcome": "", "Count": ""}, {"Intervention": [], "Observation": "more", "Outcome": "", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID-19 .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 113}], "Intervention": [{"term": "Therapeutic enoxaparin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 22}], "Outcome": [{"term": "gas exchange", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 44}, {"term": "need for mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 94}], "Observation": [{"term": "improves", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 31}, {"term": "decreases", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 58}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : REBEC RBR-949z6v .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "REBEC RBR-949z6v", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 37}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}